Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $85.0 million
Deal Type : Series A Financing
Stylus Outlines Next-Gen Gene Editing Mission with $85M in Hand
Details : Stylus will use this financing to advance its in vivo genetic medicines. The company’s elegant engineering platform combines sequence-specific genome integration with cell-targeted LNP delivery.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $85.0 million
Deal Type : Series A Financing
Reset All
